ReviewActa pharmaceutica Sinica. B2018
3D tissue engineering, an emerging technique for pharmaceutical research.
Review in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 67 citations in OpenAlex.
- Heat Shock Protein Inhibitor Tanespimycin (17AAG) Suppresses SARS-CoV-2 Main Protease Activity and Is More Potent Than Clinically Approved Antiviral Nirmatrelvir.Chembiochem : a European journal of chemical biology · 2026Article
- Injectable hydrogel-based localized delivery of IDO-galectin-3 mitigates neuroinflammation and promotes neuronal sparing after spinal cord contusion in rats.Journal of materials chemistry. B · 2026Article
- In vitro evaluation of a decellularized human fetal skin-derived scaffold repopulated with human amniotic fluid stem cells for potential application in myelomeningocele repair.Scientific reports · 2026Article
- Chemoselective Characterization of New Extracellular Matrix Deposition in Bioengineered Tumor Tissues.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Bioprinted Four-Cell-Type Lung Model for Viral Infection Studies Under Air-Liquid Interface Conditions.International journal of molecular sciences · 2025Article
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- Immune-mediated disruption of the blood-brain barrier after intracerebral hemorrhage: Insights and potential therapeutic targets.CNS neuroscience & therapeutics · 2024Review
- Development of 3D skin equivalents for application in photodynamic biostimulation therapy assays using curcumin nanocapsules.Heliyon · 2024Article
- Phenotypic Screening of Prospective Analgesics Among FDA-Approved Compounds using an iPSC-Based Model of Acute and Chronic Inflammatory Nociception.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Recent progresses in neural tissue engineering using topographic scaffolds.American journal of stem cells · 2024Review
- Emerging trends in organ-on-a-chip systems for drug screening.Acta pharmaceutica Sinica. B · 2023Review
- Systematic Comparison of Commercial Hydrogels Revealed That a Synergy of Laminin and Strain-Stiffening Promotes Directed Migration of Neural Cells.ACS applied materials & interfaces · 2023Article
- 3D engineered tissue models for studying human-specific infectious viral diseases.Bioactive materials · 2023Review
- Recent progress in the manipulation of biochemical and biophysical cues for engineering functional tissues.Bioengineering & translational medicine · 2023Review
- Engineering cerebral folding in brain organoids.Neural regeneration research · 2022Article
- The Natural Products Withaferin A and Withanone from the Medicinal HerbJournal of natural products · 2022Article
- Tissue-Engineered Models of the Human Brain: State-of-the-Art Analysis and Challenges.Journal of functional biomaterials · 2022Review
- Travelling-Wave and Asymptotic Analysis of a Multiphase Moving Boundary Model for Engineered Tissue Growth.Bulletin of mathematical biology · 2022Article
- Human Heart Anoxia and Reperfusion Tissue (HEART) Model for the Rapid Study of Exosome Bound miRNA Expression As Biomarkers for Myocardial Infarction.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Highlights on Advancing Frontiers in Tissue Engineering.Tissue engineering. Part B, Reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tissue engineering and the tissue engineering model have shown promise in improving methods of drug delivery, drug action, and drug discovery in pharmaceutical research for the attenuation of the central nervous system inflammatory response. Such inflammation contributes to the lack of regenerative ability of neural cells, as well as the temporary and permanent loss of function associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. This review is focused specifically on the recent advances in the tissue engineering model made by altering scaffold biophysical and biochemical properties for use in the treatment of neurodegenerative diseases. A portion of this article will also be spent on the review of recent progress made in extracellular matrix decellularization as a new and innovative scaffold for disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.